CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer.
  
  LEARNING OBJECTIVES

  • Consider available clinical research with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer, and counsel appropriate patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for recurrent ovarian cancer in order to optimally incorporate these agents into the care of appropriate patients.
  • Appreciate the biologic rationale for and published clinical research with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for ovarian cancer management.
  • Recognize the rationale for targeting folate receptor alpha in ovarian cancer, and determine optimal methods to test for this newly relevant biomarker and the current role of novel approaches to therapeutically exploit it.
  • Appreciate the incidence of sodium-dependent phosphate transport protein 2b expression in ovarian cancer, and evaluate published research findings with and ongoing clinical trials assessing investigational agents designed to exploit this potential therapeutic target.
  • Describe the scientific rationale for tumor treating fields as a therapeutic approach for patients with ovarian cancer, and appraise the available efficacy and safety data with this strategy delivered in combination with chemotherapy for recurrent, advanced disease.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for ovarian cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Mansoor Raza Mirza, MD
  Chief Oncologist
  Copenhagen University Hospital
  Medical Director
  Nordic Society of Gynaecological Oncology – Clinical Trial Unit
  Vice President, European Society of Gynaecological Oncology
  Copenhagen, Denmark
  
  Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GSK, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Zai Lab; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GSK, Karyopharm Therapeutics, Merck, Novartis, Roche Laboratories Inc, Zai Lab; Nonrelevant Financial Relationship: Chairman 2020-2022, European Network of Gynaecological Trial Groups.
  
  Amit M Oza, MD
  Bergsagel Chair in Medical Oncology
  Professor of Medicine
  University of Toronto
  Head, Division of Medical Oncology and Hematology
  Director, Clinical Cancer Research and BRAS Drug Development Program
  Princess Margaret Cancer Centre
  UHN and Mount Sinai Health System
  Toronto, Ontario, Canada
  
  No relevant conflicts of interest to disclose.
  
  Richard T Penson, MD, MRCP
  Associate Professor of Medicine
  Harvard Medical School
  Clinical Director, Medical Gynecologic Oncology
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Nonrelevant Financial Relationship: BMJ Publishing Group Ltd, Elsevier, UptoDate, Wiley-Blackwell, Wolters Kluwer Health.
  
  MODERATOR
  
  Joyce F Liu, MD, MPH
  Associate Chief and Director of Clinical Research
  Division of Gynecologic Oncology
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GSK, Regeneron Pharmaceuticals Inc; Consulting Agreement: Bristol-Myers Squibb Company; Trial Support (to Institution for Study Conduct): 2X Oncology Inc, Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, CytomX Therapeutics, GSK, Impact Therapeutics, Regeneron Pharmaceuticals Inc, Vigeo Therapeutics, Zentalis Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, and Novocure Inc.
  
  Release date: April 2023
  Expiration date: April 2024